FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602169105> ?p ?o ?g. }

• W2602169105 endingPage "3174" @default.
• W2602169105 startingPage "3165" @default.
• W2602169105 abstract "Abstract Selinexor is a novel, first-in-class, selective inhibitor of nuclear export compound, which blocks exportin 1 (XPO1) function, leads to nuclear accumulation of tumor suppressor proteins, and induces cancer cell death. A phase 1 dose-escalation study was initiated to examine the safety and efficacy of selinexor in patients with advanced hematological malignancies. Ninety-five patients with relapsed or refractory acute myeloid leukemia (AML) were enrolled between January 2013 and June 2014 to receive 4, 8, or 10 doses of selinexor in a 21- or 28-day cycle. The most frequently reported adverse events (AEs) in patients with AML were grade 1 or 2 constitutional and gastrointestinal toxicities, which were generally manageable with supportive care. The only nonhematological grade 3/4 AE, occurring in &gt;5% of the patient population, was fatigue (14%). There were no reported dose-limiting toxicities or evidence of cumulative toxicity. The recommended phase 2 dose was established at 60 mg (∼35 mg/m2) given twice weekly in a 4-week cycle based on the totality of safety and efficacy data. Overall, 14% of the 81 evaluable patients achieved an objective response (OR) and 31% percent showed ≥50% decrease in bone marrow blasts from baseline. Patients achieving an OR had a significant improvement in median progression-free survival (PFS) (5.1 vs 1.3 months; P = .008; hazard ratio [HR], 3.1) and overall survival (9.7 vs 2.7 months; P = .01; HR, 3.1) compared with nonresponders. These findings suggest that selinexor is safe as a monotherapy in patients with relapsed or refractory AML and have informed subsequent phase 2 clinical development. This trial was registered at www.clinicaltrials.gov as #NCT01607892." @default.
• W2602169105 created "2017-04-07" @default.
• W2602169105 creator A5000885506 @default.
• W2602169105 creator A5022339242 @default.
• W2602169105 creator A5033009352 @default.
• W2602169105 creator A5033974204 @default.
• W2602169105 creator A5036560661 @default.
• W2602169105 creator A5036866696 @default.
• W2602169105 creator A5049400849 @default.
• W2602169105 creator A5050484646 @default.
• W2602169105 creator A5051352882 @default.
• W2602169105 creator A5055906478 @default.
• W2602169105 creator A5056314507 @default.
• W2602169105 creator A5061973648 @default.
• W2602169105 creator A5070373312 @default.
• W2602169105 creator A5071023119 @default.
• W2602169105 creator A5071420169 @default.
• W2602169105 creator A5077110117 @default.
• W2602169105 creator A5079262854 @default.
• W2602169105 creator A5082283453 @default.
• W2602169105 creator A5083579907 @default.
• W2602169105 date "2017-06-15" @default.
• W2602169105 modified "2023-10-16" @default.
• W2602169105 title "A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia" @default.
• W2602169105 cites W1534965621 @default.
• W2602169105 cites W1600365609 @default.
• W2602169105 cites W1952112347 @default.
• W2602169105 cites W1964824076 @default.
• W2602169105 cites W1968110789 @default.
• W2602169105 cites W1970537520 @default.
• W2602169105 cites W1970743655 @default.
• W2602169105 cites W1974073852 @default.
• W2602169105 cites W1976233870 @default.
• W2602169105 cites W1987452803 @default.
• W2602169105 cites W2002717016 @default.
• W2602169105 cites W2008743974 @default.
• W2602169105 cites W2009386327 @default.
• W2602169105 cites W2027672647 @default.
• W2602169105 cites W2030048487 @default.
• W2602169105 cites W2032054503 @default.
• W2602169105 cites W2041817118 @default.
• W2602169105 cites W2042742519 @default.
• W2602169105 cites W2061782012 @default.
• W2602169105 cites W2062233810 @default.
• W2602169105 cites W2066599338 @default.
• W2602169105 cites W2086280295 @default.
• W2602169105 cites W2109065151 @default.
• W2602169105 cites W2109611268 @default.
• W2602169105 cites W2111064444 @default.
• W2602169105 cites W2115943711 @default.
• W2602169105 cites W2137881702 @default.
• W2602169105 cites W2147338626 @default.
• W2602169105 cites W2158670561 @default.
• W2602169105 cites W2159089429 @default.
• W2602169105 cites W2159507916 @default.
• W2602169105 cites W2159746057 @default.
• W2602169105 cites W2170515966 @default.
• W2602169105 cites W2290633618 @default.
• W2602169105 cites W2462779032 @default.
• W2602169105 cites W2495597122 @default.
• W2602169105 cites W2590580944 @default.
• W2602169105 cites W4239330499 @default.
• W2602169105 doi "https://doi.org/10.1182/blood-2016-11-750158" @default.
• W2602169105 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5524530" @default.
• W2602169105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28336527" @default.
• W2602169105 hasPublicationYear "2017" @default.
• W2602169105 type Work @default.
• W2602169105 sameAs 2602169105 @default.
• W2602169105 citedByCount "105" @default.
• W2602169105 countsByYear W26021691052017 @default.
• W2602169105 countsByYear W26021691052018 @default.
• W2602169105 countsByYear W26021691052019 @default.
• W2602169105 countsByYear W26021691052020 @default.
• W2602169105 countsByYear W26021691052021 @default.
• W2602169105 countsByYear W26021691052022 @default.
• W2602169105 countsByYear W26021691052023 @default.
• W2602169105 crossrefType "journal-article" @default.
• W2602169105 hasAuthorship W2602169105A5000885506 @default.
• W2602169105 hasAuthorship W2602169105A5022339242 @default.
• W2602169105 hasAuthorship W2602169105A5033009352 @default.
• W2602169105 hasAuthorship W2602169105A5033974204 @default.
• W2602169105 hasAuthorship W2602169105A5036560661 @default.
• W2602169105 hasAuthorship W2602169105A5036866696 @default.
• W2602169105 hasAuthorship W2602169105A5049400849 @default.
• W2602169105 hasAuthorship W2602169105A5050484646 @default.
• W2602169105 hasAuthorship W2602169105A5051352882 @default.
• W2602169105 hasAuthorship W2602169105A5055906478 @default.
• W2602169105 hasAuthorship W2602169105A5056314507 @default.
• W2602169105 hasAuthorship W2602169105A5061973648 @default.
• W2602169105 hasAuthorship W2602169105A5070373312 @default.
• W2602169105 hasAuthorship W2602169105A5071023119 @default.
• W2602169105 hasAuthorship W2602169105A5071420169 @default.
• W2602169105 hasAuthorship W2602169105A5077110117 @default.
• W2602169105 hasAuthorship W2602169105A5079262854 @default.
• W2602169105 hasAuthorship W2602169105A5082283453 @default.
• W2602169105 hasAuthorship W2602169105A5083579907 @default.
• W2602169105 hasBestOaLocation W26021691051 @default.
• W2602169105 hasConcept C121608353 @default.

• next